Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response

Mara P. Steinkamp · 2025-08-01

2Citations
While most ovarian cancer (OC) patients respond to front-line platinum/taxane chemotherapy and surgical debulking, the majority will develop platinum-resistance and recur. Our study investigated how tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) affect chemotherapy outcomes using OC patient-derived organoids and humanized patient-derived xenografts (huPDX).
Links
DOIPubMed
Journal
OncoImmunology
TL;DR

It is demonstrated that TAMs influence response to paclitaxel in both patient-derived OC organoids and huPDX, which are useful for evaluating immunomodulatory therapy effects and could serve as a robust platform for preclinical testing of novel anti-cancer treatments.

AI-generated by Semantic Scholar

Institutions
University Of New Mexico
Authors
Mara P. Steinkamp
Funding
Early Career Cancer Clinical Investigator Award (ECIA)American Cancer Society Grant IRG Pilot GrantUNMCCC FundingUNM Pathology Department Pathology Research Grant FundingUNM Pathology Department FundingUNM HSC Undergraduate Pipeline Network Summer Research Program Funding

NCI NIH HHS

P30 CA118100